1. Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism.
Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. (A to E) Serial tail volume measurements of conditions with LTB4 antagonism before initial lymphangiogenesis period: Alox5−/− mice (n = 25) (A), Ltb4r1−/− mice (n = 10) (B), WT mice treated with shLtb4r1 lentivirus on day(−7) (shLtb4r1 pretx, n = 8) (C), and WT animals treated with bestatin started on day 0 (bestatin pretx, n = 6) (D) or with Ly started on day 0 (Ly pretx, n = 6) (E). (F and G) Quantification of dermal thickness (F) and lymphatic area (G) in the day 24 tail skin for (A) to (E); n = 5. (H) Quantitations of tail volume on postsurgical day 24 for various groups. (I) Relative mRNA expression of key lymphangiogenic factors in the mouse tail skin harvested on day 24 were measured by qRT-PCR. Results were normalized to the saline-treated group. Green indicates an increased average fold change; red indicates a decreased fold change; n = 5. For (A) to (G), data are presented as means and SEM; for (H), data are presented in box-and-whiskers plots showing minimal to maximal values and all data points; comparisons with the saline-treated groups were made by Kruskal-Wallis test followed by Dunn’s multiple comparisons test for post hoc analyses.
Wen Tian et al., Sci Transl Med 2017;9:eaal3920
Published by AAAS